Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines

被引:41
|
作者
Hegerle, Nicolas [1 ]
Guiso, Nicole
机构
[1] Inst Pasteur, Unite Prevent & Therapies Mol Malad Humaines, F-75015 Paris, France
关键词
acellular vaccine; autotransporter; bacterial evolution; Bordetella pertussis; pertactin; vaccine selection; ADENYLATE-CYCLASE TOXIN; VIRULENCE FACTORS; WHOLE-CELL; FILAMENTOUS HEMAGGLUTININ; BOOSTER VACCINATION; NEGATIVE VARIANTS; GENOMIC CONTENT; WHOOPING-COUGH; PARAPERTUSSIS; IMMUNITY;
D O I
10.1586/14760584.2014.932254
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Bordetella pertussis causes whooping cough in humans, a highly transmissible respiratory disease life threatening for unvaccinated infants. Vaccination strategies were thus introduced worldwide with great success in developed countries reaching high vaccine coverage with efficacious vaccines. In the late 20th/early 21st century, acellular pertussis vaccines replaced whole cell pertussis vaccines but B. pertussis still circulates and evolves in humans, its only known reservoir. The latest transformation of this pathogen, and of its close relative Bordetella parapertussis, is the loss of pertactin production, a virulence factor included in different acellular pertussis vaccines. The real impact of this evolution on acellular pertussis vaccines efficacy and effectiveness should be assessed through standardized surveillance and isolation of B. pertussis and B. parapertussis worldwide.
引用
收藏
页码:1135 / 1146
页数:12
相关论文
共 50 条
  • [31] Polymorphism of repeated regions of pertactin in Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica
    Boursaux-Eude, C
    Guiso, N
    INFECTION AND IMMUNITY, 2000, 68 (08) : 4815 - 4817
  • [32] Crucial role of antibodies to pertactin in Bordetella pertussis immunity
    Hellwig, SMM
    Rodriguez, ME
    Berbers, GAM
    de Winkel, JGJV
    Mooi, FR
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (05): : 738 - 742
  • [33] Bordetella pertussis isolates, Finland
    Mäkinen, J
    Mertsola, J
    Mooi, FR
    Van Amersfoorth, S
    Arvilommi, H
    Viljanen, MK
    He, QS
    EMERGING INFECTIOUS DISEASES, 2005, 11 (01) : 183 - 184
  • [34] New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates
    Bouchez, Valerie
    Hegerle, Nicolas
    Strati, Francesco
    Njamkepo, Elisabeth
    Guiso, Nicole
    VACCINES, 2015, 3 (03): : 751 - 770
  • [35] Construction and evaluation of a pertactin-deficient live attenuated pertussis vaccine candidate BPZE1 derivative
    Solans, Luis
    Debrie, Anne-Sophie
    Coutte, Loic
    Locht, Camille
    VACCINE, 2021, 39 (21) : 2843 - 2849
  • [36] High prevalence of currently circulating Bordetella pertussis isolates not producing vaccine antigen pertactin in Slovenia
    Kastrin, T.
    Barkoff, A-M.
    Paragi, M.
    Vitek, M. G.
    Mertsola, J.
    He, Q.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (02) : 258 - 260
  • [37] Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland
    Gzyl, A
    Augustynowicz, E
    van Loo, I
    Slusarczyk, J
    VACCINE, 2001, 20 (3-4) : 299 - 303
  • [38] Analysis of BvgA activation of the pertactin gene promoter in Bordetella pertussis
    Kinnear, SM
    Boucher, PE
    Stibitz, S
    Carbonetti, NH
    JOURNAL OF BACTERIOLOGY, 1999, 181 (17) : 5234 - 5241
  • [39] Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom (vol 69, pg 5520, 2001)
    Fry, NK
    Neal, S
    Harrison, TG
    Miller, E
    Matthews, R
    George, RC
    INFECTION AND IMMUNITY, 2001, 69 (10) : 6564 - 6564
  • [40] Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999–2003
    Shane Byrne
    Andrew T Slack
    BMC Infectious Diseases, 6